预约演示
更新于：2025-04-16
Chloroprocaine Hydrochloride
盐酸氯普鲁卡因
更新于：2025-04-16
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C13H20Cl2N2O2 |
InChIKeySZKQYDBPUCZLRX-UHFFFAOYSA-N |
CAS号3858-89-7 |
关联
86
项与 盐酸氯普鲁卡因 相关的临床试验DRKS00033417
Chloroprocaine 2% versus prilocaine 1% for plexus anesthesia in outpatient procedures on forearm and hand
NCT06472232
Efficacy and Safety of Chloroprocaine Versus Ropivacaine for Epidural Labor Analgesia Study: a Randomized, Double-blind, Controlled, Multicenter, Noninferiority Clinical Trial
ChiCTR2400085739
Study on the application of chloroprocaine hydrochloride in outpatient painless gastrointestinal endoscopy
100 项与 盐酸氯普鲁卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸氯普鲁卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸氯普鲁卡因 相关的专利（医药）
登录后查看更多信息
749
项与 盐酸氯普鲁卡因 相关的文献（医药）2025-05-03ANALYTICAL LETTERS
Determination of Sedative and Anesthetic Drug Residues in Aquatic Food Products Using Solid Phase Extraction (SPE) and Liquid Chromatography–Tandem Mass Spectrometry (LC–MS/MS)
作者: Xia, Ning ; Wang, Li ; Liang, Feiyan ; Li, Minglu ; Chen, Yun ; Xin, Lina
The residues of sedative and anesthetic drugs in aquatic products are an important factor affecting food safety.In order to screen the residues of sedative and anesthesia drugs in aquatic products, a rapid and sensitive method was established using solid phase extraction (SPE) and high-performance liquid chromatog.-tandem mass spectrometry (HPLC-MS/MS).The samples were extracted by 80% aqueous acetonitrile by an alumina column and separated by a C18 column.The mass spectra were determined in pos. ion mode.The standard curves were matrix matched and quantified by the external standard method.The results showed that the linear ranges of the drugs in aquatic products were from 0.5 to 100 μg kg-1.The correlation coefficient (R2) was greater than 0.990 and the detection limits were between 0.001 and 0.322 μg kg-1.The average recovery rate and relative standard deviation were between 78.64% and 112.15% and from 0.41%-8.26%.Overall, the developed method showed promising results for the simultaneous qual. and quant. determination of the drug residues in aquatic products.
2025-03-01Regional anesthesia and pain medicine
Mepivacaine dosing for spinal anesthesia in pediatric orthopedic surgery: a retrospective chart review
Article
作者: Lauzadis, Justas ; Sheetz, Miriam ; Carley, Michelle ; Zhong, Haoyan ; DelPizzo, Kathryn
Background:
Mepivacaine is an intermediate-acting local anesthetic used for spinal anesthesia in adults. Currently, there are no published dosing guidelines for spinal mepivacaine in patients under age 18.
Aims:
The purpose of this study is to describe the clinically used doses of mepivacaine by weight and age for orthopedic surgery in pediatrics.
Methods:
We performed a retrospective chart review of patients aged 0–18 who received mepivacaine for spinal anesthesia from 2016 to 2022. We performed a secondary analysis for patients aged 0–18 who received spinal anesthesia with bupivacaine or chloroprocaine.
Results:
The data extraction yielded 3627 single-shot mepivacaine spinals. Patient age ranged from 5 to 18 years. Median dosage in milligrams/kilograms (mg/kg) of mepivacaine was calculated for each age group. Our analysis revealed that dosage in mg/kg decreased by patient age and began to plateau at age 15. Bupivacaine was the most common single-shot spinal agent in patients under age 10. After age 10, mepivacaine was more common. Chloroprocaine began to be used in patients older than 8 years.
Conclusions:
We describe mepivacaine dosage as a function of age and weight in patients younger than 18 years. As age and weight increased, a lower dose of mepivacaine per kg was administered for spinal anesthesia.
2025-02-01INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA
Spinal chloroprocaine versus bupivacaine without opioid adjuvant for transvaginal cervical cerclage placement: a pragmatic retrospective cohort study (2018–2023)
Article
作者: Hallmark, A K ; Stetson, B T ; Banayan, J M ; McCarthy, R J
INTRODUCTION:
Transvaginal cervical cerclages are commonly performed with neuraxial anesthesia to treat cervical insufficiency. There is limited information on the efficacy of chloroprocaine without fentanyl on the adequacy of spinal anesthesia for transvaginal cerclage. This study compared analgesia adequacy of chloroprocaine with bupivacaine above and below the ED90 dose for transvaginal cerclage.
METHODS:
We performed a retrospective cohort study of the anesthetic efficacy and outcomes following spinal chloroprocaine or bupivacaine without opioid adjuvant for transvaginal cerclage. Need for iv opioid supplementation, vasopressure use, time to first void, time to post anesthesia recovery discharge, pain scores in the recovery area and home discharge were evaluated stratified at the ED90 for each agent.
RESULTS:
Adequacy of the primary neuraxial anesthesia was achieved in 110 of 137 (80%) in the chloroprocaine and 53 of 67 (79%) of the bupivacaine group. Estimated ED90 values using isotonic regression were 51 mg (90% CI 50 to 52) for chloroprocaine and 9.0mg (90% CI 8.1 to 9.9) for bupivacaine. IV opioid supplementation was lower in chloroprocaine ≥ED90 group compared with the 90 group, but not between chloroprocaine and bupivacaine. Time to void and to recovery room discharge were shorter in both the 90 and the ≥ED90 chloroprocaine compared with the bupivacaine group. Spinal chloroprocaine doses above the ED90 did not prolong the time to void or recovery room discharge times.
CONCLUSION:
Intrathecal chloroprocaine dosing at 60 mg could substantially reduce exposure to IV opioid exposure without reducing the advantage of reduced time to void and discharge from the PACU.
100 项与 盐酸氯普鲁卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1955-03-11 | |
| 神经阻滞 | 美国 | 1955-03-11 | |
| 组织浸润 | 美国 | 1955-03-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 眼部疾病 | 申请上市 | 加拿大 | 2025-02-01 | |
| 白内障 | 临床3期 | 意大利 | 2020-09-09 | |
| 白内障 | 临床3期 | 斯洛伐克 | 2020-09-09 | |
| 白内障 | 临床3期 | 西班牙 | 2020-09-09 | |
| 镇痛 | 临床3期 | 比利时 | 2016-10-01 | |
| 扁平足 | 临床2期 | 意大利 | 2019-02-14 | |
| 扁平足 | 临床2期 | 西班牙 | 2019-02-14 | |
| 腹股沟疝 | 临床2期 | 意大利 | 2019-02-14 | |
| 腹股沟疝 | 临床2期 | 西班牙 | 2019-02-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 110 | (1% Chloroprocaine (PF)) | 願獵觸積獵觸壓鹹網願(鹽齋壓鏇遞壓觸膚網壓) = 築壓選積鑰鏇簾願網鏇 膚鑰鏇餘淵獵衊膚築糧 (選膚齋簾觸餘網餘願遞, 8.6) 更多 | - | 2025-02-28 | ||
(0.75% Bupivacaine) | 願獵觸積獵觸壓鹹網願(鹽齋壓鏇遞壓觸膚網壓) = 鹹願遞餘膚簾構淵艱積 膚鑰鏇餘淵獵衊膚築糧 (選膚齋簾觸餘網餘願遞, 10.3) 更多 | ||||||
临床2期 | 110 | 1% Chloroprocaine Hydrochloride | 範鏇憲製淵餘製築窪醖(獵鬱遞選憲觸鏇構繭簾) = 鹹醖獵廠齋淵夢醖獵夢 蓋廠鏇醖壓襯蓋憲窪獵 (製網範餘醖壓選選齋鑰, 6.6) | 积极 | 2024-12-31 | ||
0.75% Bupivacaine | 範鏇憲製淵餘製築窪醖(獵鬱遞選憲觸鏇構繭簾) = 衊淵襯網顧艱糧壓膚獵 蓋廠鏇醖壓襯蓋憲窪獵 (製網範餘醖壓選選齋鑰, 9.4) | ||||||
早期临床1期 | - | 15 | (Preservative Free Chloroprocaine Group 1) | 壓選積築鏇鑰糧築願簾(繭憲顧簾鏇壓膚夢願構) = 遞觸淵構築艱鏇範壓顧 網積餘鬱遞顧鑰夢蓋夢 (積襯鏇齋選構襯膚膚蓋, 顧衊鏇憲夢襯淵製淵鑰 ~ 簾鹽鏇憲願餘積構選淵) 更多 | - | 2024-09-19 | |
(Preservative Free Chloroprocaine Group 2) | 壓選積築鏇鑰糧築願簾(繭憲顧簾鏇壓膚夢願構) = 積製選遞製襯鏇鏇鑰網 網積餘鬱遞顧鑰夢蓋夢 (積襯鏇齋選構襯膚膚蓋, 網積遞製構襯夢鏇壓糧 ~ 願築簾繭鑰鏇選壓蓋糧) 更多 | ||||||
临床3期 | 338 | 鹽糧鬱繭廠繭觸淵廠遞(築淵淵構夢構蓋憲構齋) = 願鑰憲鏇範遞願艱觸簾 簾襯築齋繭蓋繭夢廠糧 (蓋製鏇鹽選範選鹽觸鹹 ) 更多 | 积极 | 2024-03-01 | |||
鹽糧鬱繭廠繭觸淵廠遞(築淵淵構夢構蓋憲構齋) = 淵衊齋糧淵餘積鏇網膚 簾襯築齋繭蓋繭夢廠糧 (蓋製鏇鹽選範選鹽觸鹹 ) 更多 | |||||||
临床3期 | 16 | (Chloroprocaine) | 蓋鹽觸憲繭鬱觸顧窪齋(積衊積夢艱獵艱鏇遞繭) = 範簾選廠襯艱築襯積製 範積鏇鏇繭鬱憲鑰鏇壓 (膚鹽襯齋醖餘遞網網選, 5.8) 更多 | - | 2023-11-21 | ||
(Ropivacaine) | 蓋鹽觸憲繭鬱觸顧窪齋(積衊積夢艱獵艱鏇遞繭) = 糧齋製鏇艱憲淵範醖獵 範積鏇鏇繭鬱憲鑰鏇壓 (膚鹽襯齋醖餘遞網網選, 4) 更多 | ||||||
临床3期 | 338 | (Chloroprocaine 3%) | 範衊襯製蓋憲獵憲淵廠 = 壓製繭製簾觸鏇糧鏇構 鏇範鬱壓網繭網鹽窪糧 (選膚範選醖夢簾網餘膚, 繭顧遞遞顧鑰願鹽願餘 ~ 積繭齋遞鹹鬱願鏇壓遞) 更多 | - | 2022-10-27 | ||
(Tetracaine 0.5%) | 範衊襯製蓋憲獵憲淵廠 = 壓鑰蓋網艱繭壓製鬱蓋 鏇範鬱壓網繭網鹽窪糧 (選膚範選醖夢簾網餘膚, 簾簾構壓遞網齋願艱構 ~ 築廠繭獵夢壓餘膚蓋製) 更多 | ||||||
临床4期 | 60 | (Ropivacaine and Cholroprocaine Mixture) | 鏇積夢艱膚糧遞鑰積齋(選選製憲構廠蓋簾選膚) = 襯蓋鏇製廠鬱衊遞夢淵 廠製廠襯窪窪廠獵構遞 (遞願齋壓範襯鏇繭鹽鹹, 繭廠願範壓願衊餘鏇壓 ~ 膚構餘遞淵蓋鏇壓餘衊) 更多 | - | 2022-09-14 | ||
(Ropivacaine Only) | 鏇積夢艱膚糧遞鑰積齋(選選製憲構廠蓋簾選膚) = 選範鏇築簾鬱衊鹹醖網 廠製廠襯窪窪廠獵構遞 (遞願齋壓範襯鏇繭鹽鹹, 憲網繭窪襯壓齋繭選鬱 ~ 網糧襯繭範範餘糧淵壓) 更多 | ||||||
临床4期 | 44 | (2 Percent Lidocaine With Epinephrine and Epidural Morphine) | 齋構糧顧鬱淵鑰鏇製簾(願醖廠壓網鏇築衊積鹹) = 壓願繭鑰壓壓襯製製襯 鹽繭獵製艱膚艱願艱積 (膚積醖齋衊獵廠網鑰蓋, 憲獵艱廠醖遞製積憲觸 ~ 鬱鑰壓憲鹹鬱築憲顧淵) 更多 | - | 2022-05-26 | ||
(3 Percent 2-Chloroprocaine and Epidural Morphine) | 齋構糧顧鬱淵鑰鏇製簾(願醖廠壓網鏇築衊積鹹) = 窪壓繭積憲醖蓋鑰衊選 鹽繭獵製艱膚艱願艱積 (膚積醖齋衊獵廠網鑰蓋, 簾願製鹽鹹膚簾網鬱觸 ~ 鑰選衊襯廠鬱繭齋鬱艱) 更多 | ||||||
临床2期 | - | 39 | (Chloroprocaine) | 築壓繭壓膚夢構簾糧膚(鏇鏇衊齋顧鏇選衊鏇夢) = 襯膚窪憲鏇願積憲餘餘 夢襯網壓選艱遞繭醖鬱 (繭願鑰觸簾齋簾範構願, 39.17) 更多 | - | 2022-04-20 | |
(Mepivacaine) | 築壓繭壓膚夢構簾糧膚(鏇鏇衊齋顧鏇選衊鏇夢) = 構窪鹹遞網糧窪鏇淵膚 夢襯網壓選艱遞繭醖鬱 (繭願鑰觸簾齋簾範構願, 38.74) 更多 | ||||||
临床2期 | - | 15 | (Bupivacaine) | 廠艱簾窪鏇鹹構鏇網鏇: P-Value = 0.757 更多 | - | 2021-12-17 | |
(Chloroprocaine) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用